✦ LIBER ✦

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations

✍ Scribed by Akira Sakurada; Frances A. Shepherd; Ming-Sound Tsao

Book ID: 119935554
Publisher: CIG Media Group, LP.
Year: 2006
Tongue: English
Weight: 150 KB
Volume: 7
Category: Article
ISSN: 1525-7304
DOI: 10.3816/clc.2006.s.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mutations of the epidermal growth factor

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

✍ Tetsuya Mitsudomi; Yasushi Yatabe 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 987 KB

Mutations in the epidermal growth factor

Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers

✍ Takayuki Fukui; Tetsuya Mitsudomi 📂 Article 📅 2008 🏛 Springer Japan 🌐 Japanese ⚖ 265 KB

Timing of Epidermal Growth Factor Recept

Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations

✍ Moran, T.; Sequist, L. V. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 202 KB

Update of epidermal growth factor recept

Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer

✍ Chen, Yuh-Min 📂 Article 📅 2013 🏛 Elsevier Science 🌐 Chinese ⚖ 720 KB

Epidermal growth factor receptor mutatio

Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer : Impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors

✍ Victor Cohen; Jason S. Agulnik; Celina Ang; Goulnar Kasymjanova; Gerald Batist; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB 👁 1 views

## Abstract ## BACKGROUND: Somatic mutations in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to EGFR‐tyrosine kinase inhibitors (EGFR‐TKI) in patients with nonsmall cell lung cancer (NSCLC). ## METHODS: The authors tested the possibility that nucleoti

Epidermal growth factor receptor tyrosin

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients

✍ Roengvoraphoj, Monic; Tsongalis, Gregory J.; Dragnev, Konstantin H.; Rigas, Jame 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 695 KB